Skip to content

Evaluation of The effect of clomiphene or letrozole in the treatment of infertility

Comparison of pregnancy rate with clomiphene citrate and letrosole and clomiphene alone in infertile patients with polycystic ovary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015100223621N4
Enrollment
450
Registered
2016-01-10
Start date
2015-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility. Female infertility associated with anovulation

Interventions

Intervention 1: 100 mg daily clomiphene(Ovumid
Iran Hormone, Tehran, Iran) , the third day of menstruation to 5 days. Intervention 2: 5 mg letrozole (Letrozole 2.5
SOHA Pharmaceutical Co, Tehran, Iran) daily, the third day of menstruation to 5 days. Intervention 3: 100 mg daily clomiphene(Ovumid
Iran Hormone, Tehran, Iran) , the third day of menstruation to 5 days + 5 mg letrozole (Letrozole 2.5
SOHA Pharmaceutical Co, Tehran, Iran) daily, the third day of menstruation to 5 days.
Treatment - Drugs
100 mg daily clomiphene(Ovumid
Iran Hormone, Tehran, Iran) , the third day of menstruation to 5 days
5 mg letrozole (Letrozole 2.5
SOHA Pharmaceutical Co, Tehran, Iran) daily, the third day of menstruation to 5 days
Iran Hormone, Tehran, Iran) , the third day of menstruation to 5 days + 5 mg letrozole (Letrozole 2.5

Sponsors

Vice Chancellor for research of Iran Univercity of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with history of infertility more over than one year and diagnosis of PCOS based on the revised 2003 . Exclusion criteria: Women older than 40 years or younger than 20; fallopian tubes abnormality proved by hysterosalpingography; abnormal semen analysis for their partners according to the modified criteria of the World Health Organization; endocrine problem like hyper or hypo thyroidism, hyperprolactinemia; abnormal karyotype.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Ovulation. Timepoint: Day 11 of the Menstrual cycle. Method of measurement: Transvaginal sonography.;Pregnancy. Timepoint: After retard of mense. Method of measurement: Pregnancy test by missuring B-hCG.;The number of follicles. Timepoint: Day 11 of the menstrual cycle. Method of measurement: Transvaginal sonography.;Follicle size. Timepoint: Day 11 of the menstrual cycle. Method of measurement: Transvaginal sonography.;Endometrial thickness. Timepoint: Day 11 of menstural sicle. Method of measurement: Trans aginal sonography.

Secondary

MeasureTime frame
Multiple pregnancies. Timepoint: 4-6 weeks after menstural delay. Method of measurement: Pregnancy sonography.;Abortions under 20 weeks. Timepoint: After pegnancy. Method of measurement: Pregnancy sonography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sara Ghareh Sheikhlou

Iran University of Medical Sciences

sara_sheikhlou@yahoo.com+98 21 5563 3244

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026